|
|
|
European Biopharmaceutical Review
|
To move away from ‘all-comers’ trials, the early identification of genetic factors influencing effectiveness in patient subpopulations is key. A recent increase in the use of predictive human tissue models led to the idea for a nationwide multidisciplinary collaboration that combined assays in fresh, diseased human tissues studied ex vivo, with whole exome sequencing. This allowed genomic markers to be recognised, distinguishing patients identified by the human tissue assays as ‘good’ or ‘poor’ responders.
This Scottish pharmacogenomics project has made great strides in the understanding of chronic obstructive pulmonary disease (COPD) and inflammatory bowel diseases (IBD) by using whole exome sequencing, bioinformatics and fresh human tissue assays to relate drug response to genotype. The study findings underpin a new framework for patient stratification in clinical trials that combines in vitro and molecular informatics to improve pharma success rates and accelerate the availability of effective medications.
The most common cause of drug failure is poor efficacy at Phase 1 or 3, which is, in part, attributed to clinical trials of entire patient populations, including both ‘responders’ and ‘nonresponders’ (1,2). Precision medicine can improve the prediction of clinical efficacy by selecting only those patient subpopulations likely to gain clear benefit for trials, but such forecasts require methods to identify patient subpopulations at an early stage, ideally during preclinical testing (2-4). Human tissue data generated in early discovery via a wide range of models – including stem cells, fresh human tissues and pathological specimens – is increasingly being used in preclinical testing (5-7). Tissue samples collected from the target patient population allow researchers to directly test the effect of new drugs in systems that closely reflect the in vivo situation, providing an early prediction of efficacy. The responses of tissues from different patients when studied in vitro can vary considerably, reflecting the clinical reality of responders and non-responders.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
FlyPharma Conference Europe concludes its fourth successful year in Brussels, Belgium, 5-6 June 2018
The FlyPharma Conference Europe wrapped up for another year on 6 June,
returning with an expanded roster of speakers who provided insight into
all aspects of the pharmaceutical supply chain. The event was once again
hosted at the Sheraton Brussels Airport Hotel and the Host Partner,
Brussels Airport, as always provided speakers and insight into its own
experiences working directly with a number of supply chain stakeholders.
More info >> |
|
 |
White Papers |
 |
|
How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction
Temptime Corporation
The specialty pharmacy industry could reduce costs by $27.5 million annually (product and call center staff costs only) if visual temperature indicators were used as decision-making tools to determine if medicine should be used or returned when patients suspect heat damage. In addition, 97% of patients surveyed, who received medicine from specialty pharmacies with a visual temperature indicator included in the package, agree that they would want an indicator in all shipments and 95% agree the indicator increased their confidence in the medicines received.
More info >> |
|
 |
Industry Events |
 |
RDD Asia 2018
14-15 November 2018, Grand Hyatt Kochi, Kerala, India
A
must-attend meeting for pulmonary and nasal researchers, inhaled product
developers and vendors active in this important pharmaceutical niche.
More info >> |
|
|
